市場調査レポート
商品コード
1461946

コンパニオン診断の世界市場:製品・サービス別、技術別、適応症別、サンプルタイプ別、地域別 - 予測(~2029年)

Companion Diagnostics Market By Product, Technology, Indication, Sample Type & Region - Global Forecast to 2029

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 349 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
コンパニオン診断の世界市場:製品・サービス別、技術別、適応症別、サンプルタイプ別、地域別 - 予測(~2029年)
出版日: 2024年04月05日
発行: MarketsandMarkets
ページ情報: 英文 349 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のコンパニオン診断の市場規模は、2024年の75億米ドルから2029年には136億米ドルに達すると予測され、予測期間中のCAGRは12.6%になるとみられています。

医薬品開発におけるコンパニオン診断の重要性の高まり、がん罹患率の上昇、標的療法の採用拡大などの要因が市場成長を促進しています。

調査範囲
調査対象年 2021年~2029年
基準年 2023年
予測期間 2024年~2029年
検討単位 金額(10億米ドル)
セグメント 製品・サービス別、技術別、適応症別、サンプルタイプ別、エンドユーザー別、地域別
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ、GCC諸国

コンパニオン診断市場は製品・サービス別にアッセイ、キット・試薬、機器・システム、ソフトウェア・サービスに分類されます。2023年には、アッセイ、キット・試薬セグメントが市場で最大のシェアを占めました。これは、利用可能な製品の幅が広いこと、さまざまな治療分野でアッセイやキットの利用が増加していること、基礎研究と商業用途の両方でこれらの製品に対する需要が増加していることなどの要因によるものと考えられます。

コンパニオン診断市場は、エンドユーザー別に製薬・バイオテクノロジー企業、リファレンスラボ、CRO、その他のエンドユーザーに区分されます。

2023年には、製薬・バイオテクノロジー企業がコンパニオン診断の主要ユーザーとして際立っています。この注目すべき地位は、主に医薬品開発におけるコンパニオン診断の採用の増加、およびコンパニオン診断バイオマーカーの重要性の高まりに起因しています。さらに、個別化医療への関心の高まり、様々な疾患や障害における標的治療への切迫したニーズが、製薬・バイオテクノロジー企業におけるコンパニオン診断の需要と統合を促進すると予測されています。

アジア太平洋は予測期間中に最も高いCAGRで成長すると予想されています。この成長は、ヘルスケア支出の増加、製薬研究資金の増加、疾病の早期発見に対する認識を高めるための政府の取り組み、APAC諸国における地方への民間病院の拡大、同地域における高成長市場の存在などの要因によるものです。

当レポートでは、世界のコンパニオン診断市場について調査し、製品・サービス別、技術別、適応症別、サンプルタイプ別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 価格分析
  • 特許分析
  • 貿易分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析
  • ポーターのファイブフォース分析
  • 規制状況
  • 技術分析
  • 2024年~2025年の主な会議とイベント
  • 顧客のビジネスに影響を与える動向/混乱
  • 主な利害関係者と購入基準
  • 投資と資金調達のシナリオ

第6章 コンパニオン診断市場、製品・サービス別

  • イントロダクション
  • アッセイ、キット、試薬
  • 機器とシステム
  • ソフトウェアとサービス

第7章 コンパニオン診断市場、技術別

  • イントロダクション
  • ポリメラーゼ連鎖反応
  • In Situハイブリダイゼーション
  • 次世代シーケンシング
  • 免疫組織化学
  • その他

第8章 コンパニオン診断市場、適応症別

  • イントロダクション
  • がん
  • 神経疾患
  • 心血管疾患
  • 感染症
  • その他

第9章 コンパニオン診断市場、サンプルタイプ別

  • イントロダクション
  • 組織サンプル
  • 血液サンプル
  • その他

第10章 コンパニオン診断市場、エンドユーザー別

  • イントロダクション
  • 製薬会社・バイオテクノロジー企業
  • リファレンスラボ
  • CRO
  • その他

第11章 コンパニオン診断市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
  • GCC諸国

第12章 競合情勢

  • イントロダクション
  • 主要参入企業が採用した「勝つ権利」アプローチ
  • 収益分配分析
  • 市場シェア分析
  • 企業評価マトリックス:主要参入企業
  • 競争評価マトリックス:スタートアップ/中小企業
  • コンパニオン診断ベンダーの評価と財務指標
  • ブランド/製品比較分析
  • 競合シナリオ

第13章 企業プロファイル

  • 主要参入企業
    • F. HOFFMANN-LA ROCHE LTD.
    • AGILENT TECHNOLOGIES, INC.
    • QIAGEN
    • THERMO FISHER SCIENTIFIC INC.
    • ABBOTT
    • DANAHER
    • GUARDANT HEALTH
    • ILLUMINA, INC.
    • BIOMERIEUX
    • ICON PLC
    • MYRIAD GENETICS, INC.
    • SYSMEX CORPORATION
  • その他の企業
    • ALMAC GROUP
    • ARUP LABORATORIES
    • ABNOVA CORPORATION
    • BIOGENEX
    • INVIVOSCRIBE, INC.
    • ARCHERDX, INC.
    • Q2 SOLUTIONS
    • AMOY DIAGNOSTICS CO., LTD.
    • UNIOGEN
    • ASURAGEN, INC.
    • MESO SCALE DIAGNOSTICS, LLC
    • CREATIVE BIOLABS
    • NG BIOTECH

第14章 付録

目次
Product Code: MD 5463

The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period. Factors such as the increasing importance of companion diagnostics in drug development, rising cancer incidence, and the growing adoption of targeted therapies are driving market growth.

Scope of the Report
Years Considered for the Study2021-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsProduct & service, technology, indication, cancer type, sample type end user and region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC countries

"The assays, reagents & kits segment expected to achieve the highest growth rate in the companion diagnostics market, by product & service, during the forecast period"

The companion diagnostics market is categorized into assays, kits & reagents, instruments/systems and software & services based on product & service. In 2023, the assays, kits & reagents segment held the largest share of the market. This can be attributed to factors such as the wide range of available products, the rising utilization of assays and kits across various therapeutic fields, and the increasing demand for these products in both basic research and commercial applications.

"Pharmaceutical & biotechnology companies segment projected to account for the highest CAGR during the forecast period"

Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users.

In 2023, pharmaceutical & biotechnology companies stood out as the primary users of companion diagnostics within the market. This notable position is primarily attributed to the increasing adoption of companion diagnostics in drug development and the growing significance of companion diagnostic biomarkers. Furthermore, the rising interest in personalized medicine, along with the pressing need for targeted therapies across various diseases and disorders, is forecasted to boost the demand and integration of companion diagnostics among pharmaceutical & biotechnology companies.

"Asia Pacific: The fastest-growing region in companion diagnostics care market"

The global companion diagnostics market is divided into North America, Europe, Asia Pacific, Latin America, Middle East & Africa and the GCC Countries. The Asia Pacific region is expected to record the highest CAGR during the forecast period. This growth is attributed to factors such as increased healthcare expenditure, rising pharmaceutical research funding, government initiatives to raise awareness about early disease detection, expansion of private-sector hospitals into rural areas in various APAC countries, and the presence of high-growth markets in the region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 -35%
  • By Designation: C-level - 30%, D-level - 20%, and Others - 50%
  • By Region: North America - 42%, Europe - 31%, Asia Pacific - 20%, and Rest of the World -7%

Lists of Companies Profiled in the Report:

  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Agilent Technologies, Inc. (US)
  • QIAGEN (Netherlands)
  • Thermo Fisher Scientific Inc. (US)
  • Abbott (US)
  • Almac Group (UK)
  • Danaher (US
  • Illumina, Inc. (US)
  • bioMerieux (France)
  • Myriad Genetics, Inc. (US)
  • Sysmex Corporation (Japan)
  • ARUP Laboratories (UK)
  • Abnova Corporation (Taiwan)
  • Guardant Health (US)
  • ICON Plc (Ireland)
  • BioGenex (US)
  • Invivoscribe, Inc. (US)
  • ArcherDX, Inc. (Integrated DNA Technologies, Inc.) (US)
  • NG Biotech (France)
  • Q2 Solutions (US)
  • Amoy Diagnostics Co., Ltd. (China)
  • Uniogen (Abacus Diagnostica) (Finland)
  • Asuragen, Inc. (Bio-Techne) (US)
  • NG Biotech (France)
  • Meso Scale Diagnostics, LLC. (US)
  • Creative Biolabs (US)

Research Coverage:

This research report categorizes the companion diagnostics market by products, type, application and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies; contracts, partnerships, agreements, new product launches, mergers and acquisitions, and recent developments associated with the companion diagnostics market. Competitive analysis of upcoming startups in the companion diagnostics market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall companion diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the companion diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the companion diagnostics market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the companion diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the companion diagnostics market.
  • Competitive Assessment: In-depth assessment of market ranking, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US) and Abbott (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SEGMENTATION
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONS COVERED
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 RESEARCH LIMITATIONS
  • 1.6 MARKET STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • 2.8.1 RISK ASSESSMENT ANALYSIS
  • 2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 8 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    • FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 14 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
  • 4.2 COMPANION DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2024 VS. 2029
    • FIGURE 15 ASSAYS, KITS, AND REAGENTS TO DOMINATE MARKET IN 2029
  • 4.3 COMPANION DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2024 VS. 2029
    • FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • 4.4 COMPANION DIAGNOSTICS MARKET SHARE, BY INDICATION, 2024 VS. 2029
    • FIGURE 17 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.5 COMPANION DIAGNOSTICS MARKET SHARE, BY SAMPLE TYPE, 2024 VS. 2029
    • FIGURE 18 TISSUE SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.6 COMPANION DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029
    • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2029
  • 4.7 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Ability of CDx tests to reduce healthcare costs and increase efficiency
      • 5.2.1.2 Growing focus on targeted therapy
      • 5.2.1.3 Rising demand for personalized medicine
    • FIGURE 22 PERSONALIZED MEDICINE APPROVALS BY US FDA (2015-2022)
      • 5.2.1.4 Increasing incidence of cancer and subsequent adoption of CDx-based oncology medicine
    • FIGURE 23 GLOBAL CANCER INCIDENCE (2008-2030)
    • TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES FOR BOTH GENDERS (AGE: 0-85+), 2022 VS. 2045
      • 5.2.1.5 Growing application areas for companion diagnostics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Significant capital investment and low cost-benefit ratio
      • 5.2.2.2 High cost of companion diagnostic tests
      • 5.2.2.3 Unfavorable reimbursements
    • TABLE 2 COMPANION DIAGNOSTICS MARKET: REIMBURSEMENT GUIDELINES ACROSS REGIONS
      • 5.2.2.4 High cost of immunotherapy treatment
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing demand for next-generation sequencing
    • TABLE 3 DEALS UNDERTAKEN FOR DEVELOPMENT OF NGS-BASED COMPANION DIAGNOSTIC TESTS
      • 5.2.3.2 Growing significance of companion diagnostics in drug development
    • TABLE 4 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS
      • 5.2.3.3 Advancements in genomics research and rising clinical trials
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of healthcare professionals
      • 5.2.4.2 Limited awareness in emerging markets
  • 5.3 PRICING ANALYSIS
    • TABLE 5 INDICATIVE PRICING FOR COMPANION DIAGNOSTICS PRODUCTS
    • TABLE 6 AVERAGE SELLING PRICE OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION
  • 5.4 PATENT ANALYSIS
    • FIGURE 24 PATENT ANALYSIS OF COMPANION DIAGNOSTICS SYSTEMS (JANUARY 2014-DECEMBER 2023)
  • 5.5 TRADE ANALYSIS
    • 5.5.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
    • TABLE 7 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 8 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES
  • 5.7 SUPPLY CHAIN ANALYSIS
    • FIGURE 26 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 27 ECOSYSTEM MAP
    • TABLE 9 COMPANION DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 10 COMPANION DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 NORTH AMERICA
      • 5.10.2.1 US
      • 5.10.2.2 Canada
    • 5.10.3 EUROPE
    • TABLE 15 EUROPE: CLASSIFICATION OF DEVICES
    • 5.10.4 ASIA PACIFIC
      • 5.10.4.1 China
      • 5.10.4.2 Japan
    • TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.10.4.3 India
    • 5.10.5 LATIN AMERICA
      • 5.10.5.1 Brazil
      • 5.10.5.2 Mexico
    • 5.10.6 MIDDLE EAST
    • 5.10.7 AFRICA
  • 5.11 TECHNOLOGY ANALYSIS
    • 5.11.1 KEY TECHNOLOGIES
      • 5.11.1.1 Polymerase chain reaction (PCR)
      • 5.11.1.2 Next-generation sequencing (NGS)
    • 5.11.2 COMPLIMENTARY TECHNOLOGIES
      • 5.11.2.1 In situ hybridization (ISH)
    • 5.11.3 ADJACENT TECHNOLOGIES
      • 5.11.3.1 Immunohistochemistry (IHC)
  • 5.12 KEY CONFERENCES & EVENTS IN 2024-2025
    • TABLE 17 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.13.1 REVENUE POCKETS FOR COMPANION DIAGNOSTICS MARKET
    • FIGURE 28 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPANION DIAGNOSTICS PRODUCTS
    • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION DIAGNOSTICS PRODUCTS (%)
    • 5.14.2 BUYING CRITERIA
    • FIGURE 30 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS
    • TABLE 19 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS
  • 5.15 INVESTMENT AND FUNDING SCENARIO
    • FIGURE 31 COMPANION DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO

6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 20 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • 6.2 ASSAYS, KITS, AND REAGENTS
    • 6.2.1 INCREASING VOLUME OF CDX TESTS IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS
    • TABLE 21 ASSAYS & KITS: PRODUCTS OFFERED, BY COMPANY
    • TABLE 22 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 24 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 25 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 26 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.3 INSTRUMENTS & SYSTEMS
    • 6.3.1 LATEST ADVANCEMENTS IN NGS TECHNOLOGIES TO ENSURE MARKET GROWTH
    • TABLE 27 INSTRUMENTS & SYSTEMS: PRODUCTS OFFERED, BY COMPANY
    • TABLE 28 COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 30 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 32 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.4 SOFTWARE & SERVICES
    • 6.4.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH
    • TABLE 33 SOFTWARE & SERVICES: PRODUCTS OFFERED, BY COMPANY
    • TABLE 34 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 35 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 36 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2029 (USD MILLION
    • TABLE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 38 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022-2029 (USD MILLION)

7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 39 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • 7.2 POLYMERASE CHAIN REACTION
    • 7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
    • TABLE 40 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
    • TABLE 41 MAJOR PCR TESTS/KITS AVAILABLE
    • TABLE 42 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 43 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 44 EUROPE: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 45 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 46 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3 IN SITU HYBRIDIZATION
    • 7.3.1 INCREASING DEMAND IN SMALL TUMOR DIAGNOSTICS TO DRIVE GROWTH
    • TABLE 47 MAJOR ISH TESTS/KITS AVAILABLE
    • TABLE 48 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 49 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 50 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.4 NEXT-GENERATION SEQUENCING
    • 7.4.1 ADVANTAGES SUCH AS ACCURACY, SENSITIVITY, AND SPEED TO SUPPORT MARKET GROWTH
    • TABLE 53 MAJOR NGS TESTS/KITS AVAILABLE
    • TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 56 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 58 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.5 IMMUNOHISTOCHEMISTRY
    • 7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH
    • TABLE 59 MAJOR IHC TESTS/KITS AVAILABLE
    • TABLE 60 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 61 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 64 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.6 OTHER TECHNOLOGIES
    • TABLE 65 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 66 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 67 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 69 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)

8 COMPANION DIAGNOSTICS MARKET, BY INDICATION

  • 8.1 INTRODUCTION
    • TABLE 70 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
  • 8.2 CANCER
    • TABLE 71 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040
    • TABLE 72 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 73 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 75 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 77 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • 8.2.1 LUNG CANCER
      • 8.2.1.1 Growing demand for effective therapeutic drugs to increase CDx adoption
    • TABLE 78 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
    • TABLE 79 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 81 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 83 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • 8.2.2 BREAST CANCER
      • 8.2.2.1 Wide prevalence of breast cancer to boost market growth
    • TABLE 84 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
    • TABLE 85 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 86 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 87 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 88 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 89 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • 8.2.3 BLOOD CANCER
      • 8.2.3.1 Growing incidence of blood cancer to drive market
    • TABLE 90 ESTIMATED NUMBER OF LEUKEMIA CASES, BY REGION, 2022 VS. 2040
    • TABLE 91 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 92 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 93 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 95 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • 8.2.4 COLORECTAL CANCER
      • 8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth
    • TABLE 96 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
    • TABLE 97 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 98 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 99 EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 101 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
    • 8.2.5 OTHER CANCERS
    • TABLE 102 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 103 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 106 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.3 NEUROLOGICAL DISEASES
    • 8.3.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS
    • TABLE 107 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 108 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 111 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.4 CARDIOVASCULAR DISEASES
    • 8.4.1 INCREASING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH
    • TABLE 112 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 113 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 115 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 116 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.5 INFECTIOUS DISEASES
    • 8.5.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL GROWTH
    • TABLE 117 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 118 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 119 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 121 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.6 OTHER INDICATIONS
    • TABLE 122 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 123 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 124 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 125 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 126 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

9 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE

  • 9.1 INTRODUCTION
    • TABLE 127 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • 9.2 TISSUE SAMPLES
    • 9.2.1 COMPREHENSIVE PROFILING AND HIGH SENSITIVITY TO DRIVE MARKET
    • TABLE 128 EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTIC PRODUCTS
    • TABLE 129 COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 130 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 131 EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 132 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 133 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.3 BLOOD SAMPLES
    • 9.3.1 LESS INVASIVE METHOD-KEY FACTOR DRIVING ADOPTION
    • TABLE 134 EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTIC PRODUCTS
    • TABLE 135 COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 136 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 137 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 139 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.4 OTHER SAMPLE TYPES
    • TABLE 140 EXAMPLES OF OTHER SAMPLE-BASED COMPANION DIAGNOSTIC PRODUCTS
    • TABLE 141 COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 142 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 143 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 144 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 145 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)

10 COMPANION DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 146 COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET
    • TABLE 147 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 148 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 149 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 150 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 151 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.3 REFERENCE LABORATORIES
    • 10.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
    • TABLE 152 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 153 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 154 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 155 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 156 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.4 CONTRACT RESEARCH ORGANIZATIONS
    • 10.4.1 RISING DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS TO PROPEL GROWTH
    • TABLE 157 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 158 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 159 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 160 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 161 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.5 OTHER END USERS
    • TABLE 162 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 163 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 164 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 165 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 166 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)

11 COMPANION DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 167 COMPANION DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 11.2 NORTH AMERICA
    • TABLE 168 NUMBER OF NEW CANCER CASES IN NORTH AMERICA, BY TYPE OF CANCER, 2022 VS. 2045
    • FIGURE 32 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 169 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 170 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 171 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 172 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 173 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 174 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 175 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.2.1 NORTH AMERICA: RECESSION IMPACT
    • 11.2.2 US
      • 11.2.2.1 Increasing use of companion diagnostics for cancer treatment to boost market growth
    • TABLE 176 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
    • TABLE 177 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 178 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 179 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 180 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 181 US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 182 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing government initiatives to drive market
    • TABLE 183 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
    • TABLE 184 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 185 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 186 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 187 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 188 CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 189 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 190 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 191 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 192 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 193 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 194 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 195 EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 196 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.1 EUROPE: RECESSION IMPACT
    • 11.3.2 GERMANY
      • 11.3.2.1 Increasing healthcare expenditure to drive market
    • TABLE 197 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 198 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 199 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 200 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 201 GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 202 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 Growing life science industry and increasing focus on research to propel market
    • TABLE 203 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 204 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 205 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 206 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 207 UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 208 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.4 SWITZERLAND
      • 11.3.4.1 Strong research-oriented pharma industry to support market growth
    • TABLE 209 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 210 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 211 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 212 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 213 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 214 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.5 FRANCE
      • 11.3.5.1 Increasing government funding for research to support market growth
    • TABLE 215 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 216 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 217 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 218 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 219 FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 220 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.6 ITALY
      • 11.3.6.1 Growing geriatric population in region to drive market
    • TABLE 221 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 222 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 223 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 224 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 225 ITALY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 226 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.7 SPAIN
      • 11.3.7.1 Increasing focus on advancement of personalized medicine to drive market growth
    • TABLE 227 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 228 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 229 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 230 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 231 SPAIN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 232 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.3.8 REST OF EUROPE
    • TABLE 233 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 234 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 235 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 236 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 237 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 238 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 33 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 239 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 240 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 241 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 242 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 243 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 244 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 245 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 11.4.2 CHINA
      • 11.4.2.1 Advancements in healthcare facilities to drive market
    • TABLE 246 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
    • TABLE 247 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 248 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 249 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 250 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 251 CHINA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 252 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.3 JAPAN
      • 11.4.3.1 Increasing research initiatives to support market growth
    • TABLE 253 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
    • TABLE 254 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 255 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 256 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 257 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 258 JAPAN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 259 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.4 INDIA
      • 11.4.4.1 Increased demand for early cancer diagnosis to fuel market growth
    • TABLE 260 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
    • TABLE 261 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 262 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 263 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 264 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 265 INDIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 266 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Initiatives to enhance healthcare access and infrastructure for aging population to drive market
    • TABLE 267 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 268 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 269 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 270 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 271 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 272 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.4.6 REST OF ASIA PACIFIC
    • TABLE 273 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 274 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 275 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 276 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 277 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 278 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.5 LATIN AMERICA
    • TABLE 279 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 280 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 281 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 282 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 283 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 284 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 285 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.5.1 LATIN AMERICA: RECESSION IMPACT
    • 11.5.2 BRAZIL
      • 11.5.2.1 Increasing incidence of lifestyle diseases to favor market growth
    • TABLE 286 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 287 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 288 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 289 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 290 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 291 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.5.3 MEXICO
      • 11.5.3.1 Growing medical tourism to fuel demand for companion diagnostics
    • TABLE 292 MEXICO: NEW CANCER CASES, 2022
    • TABLE 293 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 294 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 295 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 296 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 297 MEXICO: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 298 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.5.4 REST OF LATIN AMERICA
    • TABLE 299 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 300 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 301 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 302 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 303 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 304 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
    • TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 306 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 307 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 308 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 309 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 310 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
  • 11.7 GCC COUNTRIES
    • 11.7.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
    • TABLE 311 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
    • TABLE 312 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 313 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 314 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 315 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
    • TABLE 316 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.7.2 GCC COUNTRIES: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • TABLE 317 COMPANION DIAGNOSTICS MARKET: STRATEGIES ADOPTED
  • 12.3 REVENUE SHARE ANALYSIS
    • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS (2019-2023)
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
    • TABLE 318 COMPANION DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 36 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 12.5.5 COMPANY FOOTPRINT
      • 12.5.5.1 Overall footprint
    • FIGURE 37 COMPANION DIAGNOSTICS MARKET: OVERALL FOOTPRINT
      • 12.5.5.2 Product footprint
    • TABLE 319 COMPANION DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
      • 12.5.5.3 Technology footprint
    • TABLE 320 COMPANION DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
      • 12.5.5.4 Indication footprint
    • TABLE 321 COMPANION DIAGNOSTICS MARKET: INDICATION FOOTPRINT
      • 12.5.5.5 Regional footprint
    • TABLE 322 COMPANION DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
  • 12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • FIGURE 38 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
    • 12.6.5 COMPETITIVE BENCHMARKING
    • TABLE 323 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 324 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • 12.7 VALUATION AND FINANCIAL METRICS OF COMPANION DIAGNOSTICS VENDORS
    • FIGURE 39 EV/EBITDA OF KEY VENDORS
    • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • 12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
    • FIGURE 41 PRODUCT/BRAND COMPARATIVE ANALYSIS, BY PARAMETER
    • 12.8.1 F. HOFFMANN-LA ROCHE LTD.
    • 12.8.2 AGILENT TECHNOLOGIES, INC.
    • 12.8.3 QIAGEN
    • 12.8.4 THERMO FISHER SCIENTIFIC INC.
    • 12.8.5 ABBOTT
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 325 COMPANION DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2024
    • 12.9.2 DEALS
    • TABLE 326 COMPANION DIAGNOSTICS MARKET: DEALS, JANUARY 2021-MARCH 2024

13 COMPANY PROFILES

  • (Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
  • 13.1 KEY PLAYERS
    • 13.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 327 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 328 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 329 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 330 F. HOFFMANN-LA ROCHE LTD.: DEALS
    • 13.1.2 AGILENT TECHNOLOGIES, INC.
    • TABLE 331 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 332 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 333 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS
    • TABLE 334 AGILENT TECHNOLOGIES, INC.: DEALS
    • 13.1.3 QIAGEN
    • TABLE 335 QIAGEN: COMPANY OVERVIEW
    • FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2023)
    • TABLE 336 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 337 QIAGEN: PRODUCT LAUNCHES & APPROVALS
    • TABLE 338 QIAGEN: DEALS
    • 13.1.4 THERMO FISHER SCIENTIFIC INC.
    • TABLE 339 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • TABLE 340 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 341 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS
    • TABLE 342 THERMO FISHER SCIENTIFIC INC.: DEALS
    • 13.1.5 ABBOTT
    • TABLE 343 ABBOTT: COMPANY OVERVIEW
    • FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2023)
    • TABLE 344 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 13.1.6 DANAHER
    • TABLE 345 DANAHER: COMPANY OVERVIEW
    • FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023)
    • TABLE 346 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 13.1.7 GUARDANT HEALTH
    • TABLE 347 GUARDANT HEALTH: COMPANY OVERVIEW
    • FIGURE 48 GUARDANT HEALTH: COMPANY SNAPSHOT (2023)
    • TABLE 348 GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 349 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS
    • TABLE 350 GUARDANT HEALTH: DEALS
    • TABLE 351 GUARDANT HEALTH: OTHER DEVELOPMENTS
    • 13.1.8 ILLUMINA, INC.
    • TABLE 352 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 353 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 354 ILLUMINA, INC.: PRODUCT LAUNCHES
    • TABLE 355 ILLUMINA, INC.: DEALS
    • 13.1.9 BIOMERIEUX
    • TABLE 356 BIOMERIEUX: COMPANY OVERVIEW
    • FIGURE 50 BIOMERIEUX: COMPANY SNAPSHOT (2023)
    • TABLE 357 BIOMERIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 13.1.10 ICON PLC
    • TABLE 358 ICON PLC: COMPANY OVERVIEW
    • FIGURE 51 ICON PLC: COMPANY SNAPSHOT (2023)
    • TABLE 359 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 13.1.11 MYRIAD GENETICS, INC.
    • TABLE 360 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
    • FIGURE 52 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 361 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 362 MYRIAD GENETICS, INC.: PRODUCT APPROVALS
    • TABLE 363 MYRIAD GENETICS, INC.: DEALS
    • 13.1.12 SYSMEX CORPORATION
    • TABLE 364 SYSMEX CORPORATION: COMPANY OVERVIEW
    • FIGURE 53 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 365 SYSMEX CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 366 SYSMEX CORPORATION: DEALS
    • TABLE 367 SYSMEX CORPORATION: OTHER DEVELOPMENTS
  • 13.2 OTHER PLAYERS
    • 13.2.1 ALMAC GROUP
    • TABLE 368 ALMAC GROUP: COMPANY OVERVIEW
    • 13.2.2 ARUP LABORATORIES
    • TABLE 369 ARUP LABORATORIES: COMPANY OVERVIEW
    • 13.2.3 ABNOVA CORPORATION
    • TABLE 370 ABNOVA CORPORATION: COMPANY OVERVIEW
    • 13.2.4 BIOGENEX
    • TABLE 371 BIOGENEX: COMPANY OVERVIEW
    • 13.2.5 INVIVOSCRIBE, INC.
    • TABLE 372 INVIVOSCRIBE, INC.: COMPANY OVERVIEW
    • 13.2.6 ARCHERDX, INC.
    • TABLE 373 ARCHERDX, INC.: COMPANY OVERVIEW
    • 13.2.7 Q2 SOLUTIONS
    • TABLE 374 Q2 SOLUTIONS: COMPANY OVERVIEW
    • 13.2.8 AMOY DIAGNOSTICS CO., LTD.
    • TABLE 375 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
    • 13.2.9 UNIOGEN
    • TABLE 376 UNIOGEN: COMPANY OVERVIEW
    • 13.2.10 ASURAGEN, INC.
    • TABLE 377 ASURAGEN, INC.: COMPANY OVERVIEW
    • 13.2.11 MESO SCALE DIAGNOSTICS, LLC
    • TABLE 378 MESO SCALE DIAGNOSTICS, LLC: COMPANY OVERVIEW
    • 13.2.12 CREATIVE BIOLABS
    • TABLE 379 CREATIVE BIOLABS: COMPANY OVERVIEW
    • 13.2.13 NG BIOTECH
    • TABLE 380 NG BIOTECH: COMPANY OVERVIEW
  • *Details on Business Overview, Products/Services/Solutions Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS